16 December 2022
Federal Council approves Swissmedic's strategic goals for 2023–2026
At its meeting held on 9 December 2022, the Federal Council approved the strategic goals of the Swiss Agency for Therapeutic Products (Swissmedic) for 2023–2026: Efficient, independent therapeutic products oversight, expansion of national and international cooperation, and trustworthy communication with the public remain focal points. Greater emphasis will be placed on support for innovation and advancing digitalisation in the new strategy period.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar